Compare PDSB & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDSB | NSRX |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | Israel |
| Employees | 10 | 7 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.6M | 25.8M |
| IPO Year | 2015 | N/A |
| Metric | PDSB | NSRX |
|---|---|---|
| Price | $1.25 | $2.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $9.00 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 983.1K | 49.8K |
| Earning Date | 05-13-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $1.98 |
| 52 Week High | $1.90 | $9.99 |
| Indicator | PDSB | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 72.37 | 35.90 |
| Support Level | $1.18 | $1.98 |
| Resistance Level | $1.40 | $5.20 |
| Average True Range (ATR) | 0.15 | 0.20 |
| MACD | 0.06 | 0.10 |
| Stochastic Oscillator | 83.21 | 42.19 |
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.